Teva Claims Diovan 180-Day Exclusivity, Arguing Ranbaxy ANDA Was Incomplete
This article was originally published in PharmAsia News
Teva supports citizen petition claiming Ranbaxy is ineligible for exclusivity but says that it is the actual first ANDA filer; generic has yet to launch nearly two years after Novartis’ Diovan patents expired.
You may also be interested in...
In a suit against FDA, Mylan argues that Ranbaxy’s delay in getting tentative approval for its valsartan ANDA within 30 months of submission triggered forfeiture of its 180-day marketing exclusivity.
Chamber files petition to have FTC amend its disqualification rules to have commissioners explain their rejection of recusal requests. FTC is seeking public comments on the petition.
BIO objects to guidelines seeking to block mergers that would eliminate a potential entrant in a concentrated market and give greater scrutiny to transactions that are part of a series of company deals. APhA and NCPA call for FTC to consider more factors in PBM mergers.